Stock comparison
IDEXX Laboratories
LivaNova
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
LIVN
LivaNova
Market cap
$4.06B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | LIVN | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 35D | IDXX |
| Benjamin Graham | 80A | 61D | IDXX |
| Philip Fisher | 75B | 43D | IDXX |
| Peter Lynch | 71B | 36D | IDXX |
| Joel Greenblatt | 83C | 36D | IDXX |
| Charlie Munger | 87A | 36D | IDXX |
| Terry Smith | 84A | 29F | IDXX |
Side-by-side metrics
| Metric | IDXX | LIVN |
|---|---|---|
| Market cap | $44.12B | $4.06B |
| P/E (TTM) | 39.0x | 36.9x |
| EV/EBIT | 31.6x | 18.9x |
| ROIC (TTM) | 40.66% | 10.19% |
| Gross margin | 62.05% | 67.57% |
| Net margin | 24.63% | 7.47% |
| Revenue CAGR 5y | 7.56% | 7.6% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $4.06B+91%
- ROIC (TTM)40.66%vs 10.19%+75%
- Net margin24.63%vs 7.47%+70%
LIVN leads on
- Debt / Equity0.3xvs 0.7x+60%
- EV/EBIT18.9xvs 31.6x+40%
- Gross margin67.57%vs 62.05%+8%
- P/E (TTM)36.9xvs 39.0x+6%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.